Literature DB >> 3057957

High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure.

D Dreyfuss1, P Soler, G Basset, G Saumon.   

Abstract

The respective roles of high pressure and high tidal volume to promote high airway pressure pulmonary edema are unclear. Positive end-expiratory pressure (PEEP) was shown to reduce lung water content in this type of edema, but its possible effects on cellular lesions were not documented. We compared the consequences of normal tidal volume ventilation in mechanically ventilated rats at a high airway pressure (HiP-LoV) with those of high tidal volume ventilation at a high (HiP-HiV) or low (LoP-HiV) airway pressure and the effects of PEEP (10 cm H2O) on both edema and lung ultrastructure. Pulmonary edema was assessed by extravascular lung water content and microvascular permeability by the drug lung weight and the distribution space of 125I-labeled albumin. HiP-LoV rat lungs were not different from those of controls (7 cm H2O peak pressure ventilation). By contrast, the lungs from the groups submitted to high volume ventilation had significant permeability type edema. This edema was more pronounced in LoP-HiV rats. It was markedly reduced by PEEP, which, in addition, preserved the normal ultrastructural aspect of the alveolar epithelium. This was in striking contrast to the diffuse alveolar damage usually encountered in this type of edema. To our knowledge, this constitutes the first example of a protective effect of PEEP during permeability edema.

Entities:  

Mesh:

Year:  1988        PMID: 3057957     DOI: 10.1164/ajrccm/137.5.1159

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  254 in total

1.  High frequency ventilation: basic concepts and clinical application.

Authors:  R Ramanathan; S Sardesai
Journal:  Indian J Pediatr       Date:  2000-01       Impact factor: 1.967

2.  Neutrophils and lung injury: getting it right.

Authors:  Thomas R Martin
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Vedang Londhe; Ying Ying Xue; Kewang Li; Roderick J Phillips; Robert M Strieter
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 4.  The pulmonary physician in critical care * 7: ventilator induced lung injury.

Authors:  T Whitehead; A S Slutsky
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

5.  PEEP, ARDS, and alveolar recruitment.

Authors:  J Mancebo
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 6.  The pulmonary physician and critical care. 2. The injured lung: conventional and novel respiratory therapy.

Authors:  A Swami; B F Keogh
Journal:  Thorax       Date:  1992-07       Impact factor: 9.139

7.  Standardized lung recruitment during high frequency and conventional ventilation: similar pathophysiologic and inflammatory responses in an animal model of respiratory distress syndrome.

Authors:  Ramesh K M Krishnan; Pat A Meyers; Cathy Worwa; Ronald Goertz; Galen Schauer; Mark C Mammel
Journal:  Intensive Care Med       Date:  2004-03-02       Impact factor: 17.440

8.  Early detection of deteriorating ventilation: prevention is better than cure!

Authors:  Marcelo Gama De Abreu; Andreas Güldner
Journal:  Intensive Care Med       Date:  2011-11-22       Impact factor: 17.440

9.  Modeling the time-course of ventilator-induced lung injury: what can we learn from interspecies discrepancies?

Authors:  Nicolas de Prost; Georges Saumon; Didier Dreyfuss
Journal:  Intensive Care Med       Date:  2011-11-04       Impact factor: 17.440

10.  Time to generate ventilator-induced lung injury among mammals with healthy lungs: a unifying hypothesis.

Authors:  Pietro Caironi; Thomas Langer; Eleonora Carlesso; Alessandro Protti; Luciano Gattinoni
Journal:  Intensive Care Med       Date:  2011-11-04       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.